blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…
Since early in the HIV/AIDS epidemic, the National Institute of Allergy and Infectious Diseases (NIAID) has involved community representatives and advocates in the research process. The nature and scope of the community’s involvement have grown over the years, but the rationale behind these efforts remains the same: the people who might benefit from the research…
As the National Institute of Allergy and Infectious Diseases (NIAID) moves forward to restructure its HIV/AIDS Clinical Trials Networks and include a new network focused on infectious diseases other than AIDS, the Clinical Trial Units (CTUs) will continue to play a critical role in establishing, developing, and implementing the networks’ scientific research agendas. Additionally, we…
Co-authored by Margaret (Peggy) Johnston, Ph.D., Senior Scientific Consultant, NIAID.
HIV Vaccine Awareness Day provides an opportunity to acknowledge the more than 35,000 individuals who have volunteered for preventive HIV vaccine trials over the past 25 years. Without their participation, the modest success that we have achieved…
Yesterday, we blogged that NIH released findings from an important large-scale clinical study that found that men and women living with HIV who took oral antiretroviral medicines when their immune systems were relatively healthy, were able to reduce the risk of transmitting the virus to their sexual partners. We also heard from the CDC Director…
The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.
I’ve been fortunate to attend international HIV conferences for many years. Several of those conferences stand out in my memory for the results they produced. In Vancouver (1996), researchers first announced the results of the highly active antiretroviral therapy (HAART) clinical trials—changing the future for millions of us living with HIV. In Durban (2000), delegates…
Co-authored by Margaret I. Johnston, Ph.D., Director of the Vaccine Research Program in NIAID’s Division of AIDS Carl W. Dieffenbach, PhD Margaret I. Johnston, PhD The development of a safe and effective preventive vaccine for HIV remains one of NIAID’s highest priorities. As we look to the future, we are also seeking to expand the…
